Clinical utility of tumor measurement (TM)-based metrics in phase II (P2) to predict phase III (P3) overall survival (OS) outcomes using the RECIST 1.1 database.
Sumithra J. Mandrekar
No relevant relationships to disclose
Ming-Wen An
No relevant relationships to disclose
Yu Han
No relevant relationships to disclose
Daniel J. Sargent
No relevant relationships to disclose